University of California, San Francisco

UCSF scientist over twenty-five (25) years, twenty-three as Director of the Laboratory for Cell Analysis (LCA). Currently Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine. • Built the LCA into one of the largest academic cytometry core facilities worldwide. • Direct contribution to grants totals well over $40M in extramural funding. • Helped design and build five commercial flow cytometers, two cell sorters, and two commercial confocal microscopes. Current work supports several developing technology fields including automated digital pathology and laser-based microdissection systems, next generation clinical cell sorters, spectral flow cytometry, chip-based cytometry and point-of-care devices, wide-field high-resolution deep tissue confocal microscopy, mass spec flow cytometry (CyTOF), and spectral in vivo imaging. Application development includes single cell genomics, new functional reporter probes for cell cycle, cellular biosensors, FRET/FRAP/FLIM reporters for monitoring protein and drug interactions, new encoded carrier technology for immune profiling and liquid arrays, and rapid identification systems for virology and microbiology. Hyun also participates in biomedical software and database design, and testing of new algorithms for cytometric data processing and presentation of results.

2 past transactions

ArsenalBio

Series B in 2022
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access.

Hazel Health

Series C in 2020
Hazel Health is a healthcare company that improves the health and well-being of students by increasing access to healthcare. It partners with schools and nurses, supporting student health to keep them healthy and ready to learn. With Hazel, students can talk with a doctor over the video, and get the care they need whether they are at home or in school. Its doctors provide treatment for a wide range of conditions. They can prescribe over-the-counter medicine at school with parent approval, or call in prescriptions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.